AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04789083 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Propholis extrate
Description: Plassebo
Study NCT05505305 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-restricted eating and high-intensity interval training
Description: Maximal daily eating window of 10 hours and high-intensity interval training (three weekly, unsupervised, aerobic exercise sessions performed at > 90 % heart rate maximum). Each exercise session will last for 33-38 minutes. Participants will receive digital follow-up once weekly. The intervention period will be seven weeks,
Study NCT05112718 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma Injections
Description: PRP injected into 9 sites of the distal anterior one-third of the vagina using a small 30-gauge needle. The injections were performed at 10, 12 and 2 o'clock in 3 different levels of the urethra 1-2 cm apart (distal, mid and proximal).~The participants will receive 2 PRP injections at 4-6-week intervals. Xylocaine gel 2% is applied to the distal anterior vaginal wall 20 minutes before injections.
Study NCT05112718 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Normal Saline Injections
Description: Normal saline injected into 9 sites of the distal anterior one-third of the vagina using a small 30-gauge needle. The injections were performed at 10, 12 and 2 o'clock in 3 different levels of the urethra 1-2 cm apart (distal, mid and proximal).~The participants will receive 2 injections at 4-6-week intervals.
Study NCT05549297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tebentafusp
Description: Soluble gp100-specific T cell receptor with anti-CD3 scFV
Study NCT05549297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tebentafusp with Pembrolizumab
Description: Soluble gp100-specific T cell receptor with anti-CD3 scFV in combination with pembrolizumab
Study NCT05549297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigators Choice
Description: Investigators choice of therapy
Study NCT05481411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olpasiran
Description: Subcutaneous injection
Study NCT04989829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR6390、Omeprazole
Description: SHR6390 tablet single dose、Omeprazol single dose.
Study NCT04770610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OT-101 Ophthalmic Solution
Description: Atropine 0.01%
Study NCT04770610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: Investigational Product minus active ingredient
Study NCT04770610 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Investigational Product minus active ingredient
Study NCT05206370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytisinicline
Description: film-coated oral tablets containing 3 mg cytisinicline
Study NCT05206370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: film-coated oral tablets containing matched placebo
Study NCT05206370 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: film-coated oral tablets containing matched placebo
Study NCT05206370 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral support
Description: Behavioral support sessions by a qualified study site staff member will be participant-driven and will include direct engagement with the subject about their attempt to quit smoking. Each session will last approximately 10 minutes.
Study NCT05206370 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Behavioral support
Description: Behavioral support sessions by a qualified study site staff member will be participant-driven and will include direct engagement with the subject about their attempt to quit smoking. Each session will last approximately 10 minutes.
Study NCT06419868 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Universal preventive intervention for depression and anxiety for university students
Description: This is a self-applied online intervention with six modules. It should be implemented over a period of 4 to 8 weeks. It includes emotion regulation, mindfulness exercises, coping strategies, problem-solving strategies, psychoeducation of anxiety and depression, and the development of healthy behaviors, explained through the following theoretical components: mindfulness and cognitive behavioral therapy.~Participants will be guided through the program in a structured manner. They will start by accessing the CANVAS online platform, where they will find the content of the sessions in video, audio, and text formats. They will then be directed to practice exercises at home, with audiovisual material to guide them. It's crucial that participants complete the six sessions sequentially, as each session is designed to build upon the previous one, ensuring a comprehensive learning experience and effective learning.
Study NCT05161481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avenciguat (BI 685509)
Description: Avenciguat (BI 685509)
Study NCT05161481 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching Avenciguat (BI 685509)
Description: Placebo matching Avenciguat (BI 685509)
Study NCT06099665 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Automated alert
Description: Receiving an automated alert via the EHR to highlight that the patient in question presents for severe aortic stenosis or severe mitral regurgitation according to the AHA guidelines and that they are a good candidate for valve intervention. The alert will not list any specific manufacturer's device.
Study NCT06469021 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conservative Approach
Description: Structured scoliosis exercises will be prescribed by the physiotherapist according to the severity of the curvature and cosmetics of the individuals. In a one session period, 5-minute warm-up and cool-down periods, 20 minutes of scoliosis exercises, 10 minutes of core stabilization exercises and 10 minutes of balance training will be applied. The exercises will start from an easy level and the level of difficulty will be gradually increased. The assessments will be evaluated in three stages: at the beginning of treatment, at the third month of treatment and at the end of treatment (sixth month).
Study NCT06469021 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitative Game Therapy
Description: Structured scoliosis exercises will be prescribed by the physiotherapist according to the severity of the curvature and cosmetics of the patients and will be applied to the patients with a conventional approach. In a one-session period, 5-minute warm-up and cool-down periods, 20 minutes of scoliosis exercises, 10 minutes of core stabilization exercises, and 10 minutes of balance training will be applied in the clinical setting. Home exercises will be performing with the SmartPose system differently from the control group. The SmartPose system is a special software system that enables the user to perform movements with a tablet or phone without the need for any sensors.
Study NCT06264596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: The epinephrine group will have two 3-L normal saline solution bags prepared for each case with 1 mL of 1:1000 epinephrine in each bag
Study NCT06264596 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Normal Saline irrigation fluid
Description: The control group will have two 3-L normal saline solution bags prepared with no additive
Study NCT06264596 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline irrigation fluid
Description: The control group will have two 3-L normal saline solution bags prepared with no additive
Study NCT05308004 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palliative Care Consultation
Description: Trained provider will discuss illness trajectories, establish and communicate patient-directed goals that guide health care decisions, identify and treat illness-related symptoms, and identify psycho-spiritual needs and approaches to mitigate suffering
Study NCT06381102 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcutaneous auricular vagus nerve stimulation 30/30
Description: Transauricular vagus nerve stimulation (taVNS) is a simple technique in which small surface electrodes are placed over the skin of the ear that are thought to be innervated by the auricular branch of the vagus nerve (ABVN). Participants in this group will first receive taVNS with a 30 second on and 30 second off, for 1 hour, in-person.
Study NCT06381102 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous auricular vagus nerve stimulation 30/30
Description: Transauricular vagus nerve stimulation (taVNS) is a simple technique in which small surface electrodes are placed over the skin of the ear that are thought to be innervated by the auricular branch of the vagus nerve (ABVN). Participants in this group will first receive taVNS with a 30 second on and 30 second off, for 1 hour, in-person.
Study NCT06381102 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcutaneous auricular vagus nerve stimulation 10/10
Description: Transauricular vagus nerve stimulation (taVNS) is a simple technique in which small surface electrodes are placed over the skin of the ear that are thought to be innervated by the auricular branch of the vagus nerve (ABVN). Participants in this group will first receive taVNS with a 10 second on and 10 second off, for 1 hour, in-person.
Study NCT06381102 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous auricular vagus nerve stimulation 10/10
Description: Transauricular vagus nerve stimulation (taVNS) is a simple technique in which small surface electrodes are placed over the skin of the ear that are thought to be innervated by the auricular branch of the vagus nerve (ABVN). Participants in this group will first receive taVNS with a 10 second on and 10 second off, for 1 hour, in-person.
Study NCT05145010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infigratinib
Description: Infigratinib minitablets or sprinkle capsules to be administered by mouth. In subjects that completed a prior study with infigratinib, the starting dose will be the same as the last dose received in the prior interventional study with infigratinib. Infigratinib dose may be adjusted to 0.25 mg/kg/day (the dose selected to be explored further in the dose escalation portion of Phase 2 study QBGJ398-201 (PROPEL 2)).
Study NCT05145010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infigratinib
Description: Infigratinib sprinkle capsules to be administered by mouth. Starting dose for the subjects naïve to Infigratinib will be 0.25 mg/kg/day (the dose selected to be explored further in the dose escalation portion of Phase 2 study QBGJ398-201 (PROPEL 2)).
Study NCT06637644 — intervention group
Intervention type: DEVICE
Intervention: Right-sided ventricular assist device
Description: Percutaneous device for right heart support
Study NCT06207435 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transportation
Description: Eligible patients are contacted and offered free transportation to and from their upcoming appointment.
Study NCT06471257 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Budesonide/Albuterol metered dose inhaler, MDI
Description: Combination Product (Drug + Device)
Study NCT06471257 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol sulfate metered dose inhaler, MDI
Description: Combination Product (Drug + Device)
Study NCT06645444 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immediate implant placement with customized PEEK healing abutment
Description: * an intraoral examination will be done and a digital impression will be taken by the intraoral scanner (MEDIT i500) for a pre-extraction digital model, and CBCT will be taken for prosthetic-driven planning.~* Once the treatment plan formulated, both STL (Standard Triangle Language) and DICOM (CBCT raw data) files format will be sent to produce the digital surgical guide with metal sleeve.~* Then, a customized PEEK healing abutment will be made mimicking the anatomical cervical contour and pseudo-CEJ will be made by merging the STL and DICOM digitally and the exterior surface of the healing abutment will be designed to resemble a tooth.~* Then, the technicians will mill the customized healing abutment digital design from a pre-milled 14 × 14 mm PEEK block (BioHPP, Bredent®, Bolzano, Italy) with a non-hex connection type, polished it, and sterilized it.~* The digital surgical guide with a metal sleeve will be back for scheduled patient implant surgery.
Study NCT06645444 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: immediate implant placement with customized PEEK healing abutment
Description: * an intraoral examination will be done and a digital impression will be taken by the intraoral scanner (MEDIT i500) for a pre-extraction digital model, and CBCT will be taken for prosthetic-driven planning.~* Once the treatment plan formulated, both STL (Standard Triangle Language) and DICOM (CBCT raw data) files format will be sent to produce the digital surgical guide with metal sleeve.~* Then, a customized PEEK healing abutment will be made mimicking the anatomical cervical contour and pseudo-CEJ will be made by merging the STL and DICOM digitally and the exterior surface of the healing abutment will be designed to resemble a tooth.~* Then, the technicians will mill the customized healing abutment digital design from a pre-milled 14 × 14 mm PEEK block (BioHPP, Bredent®, Bolzano, Italy) with a non-hex connection type, polished it, and sterilized it.~* The digital surgical guide with a metal sleeve will be back for scheduled patient implant surgery.
Study NCT05595239 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: blood purification(CVVH)
Description: After the sepsis patients were enrolled, they were treated with blood purification in CVVH mode, 24 hours per day, for 3 consecutive days
Study NCT05595239 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: blood purification(TPE+CVVH)
Description: After the sepsis patients were enrolled, they were treated with blood purification in TPE mode 2 hours at first and then in CVVH mode 22 hours in the first two days, and then in CVVH mode 24 hours
Study NCT05595239 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: blood purification(HP+CVVH)
Description: After the sepsis patients were enrolled, they were treated with blood purification in HP mode 2 hours at first and then in CVVH mode 22 hours in the first two days, and then in CVVH mode 24 hours
Study NCT05731245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropeginterferon Alfa-2B Prefilled Syringe [Besremi]
Description: Eligible subjects will receive Ropeginterferon alfa-2b subcutaneously (SC) every 2 weeks at the starting dose of 250µg at week 0, 350 µg at week 2, then 500µg at a fixed dose from week 4 onwards
Study NCT04749706 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical training alone
Description: The physical activity intervention will consist in 12 weeks of training composed of 3 sessions per week. The three sessions will be mainly composed of resistance training aiming at increasing body weight through increased fat free mass. The main muscle groups (lower limbs, upper limbs and trunk) will be trained. The intervention will be performed under the supervision of a specialized coach.
Study NCT04749706 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical training alone
Description: The physical activity intervention will consist in 12 weeks of training composed of 3 sessions per week. The three sessions will be mainly composed of resistance training aiming at increasing body weight through increased fat free mass. The main muscle groups (lower limbs, upper limbs and trunk) will be trained. The intervention will be performed under the supervision of a specialized coach.
Study NCT04749706 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical training + protein intake
Description: The physical activity intervention will consist in 12 weeks of training composed of 3 sessions per week. The three sessions will be mainly composed of resistance training aiming at increasing body weight through increased fat free mass. The main muscle groups (lower limbs, upper limbs and trunk) will be trained. The intervention will be performed under the supervision of a specialized coach.~15 women with constitutional leanness will, on top of the physical training, received a daily protein supplementation corresponding to 20 grams of proteins + 10 grams of Maltodextrine
Study NCT05960552 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: The PReTEE group
Description: Prior to clinical application of PReTEE, all participants designated must receive professional training. They need to receive lectures focusing on the clinical thinking flowchart of rescue transesophageal echocardiography, in conjuntion with the simulator-based training. The discriminating ability of PReTEE will be further assessed in real clinical scenario, that is, within the specified 120 seconds participants in the PreTEE group need to provide the leading causes with regard to difficult separation from cardiopulmonary bypass in high-risk cardiac surgical procedures. All examinations will be supervised by a TEE expert owning to safety considerations but without help in views acquirement or interpretation. After completion of study assessments, the TEE expert will perform a standard comprehensive TEE, the results of which was reported to the attending cardiac anesthesiologist in charge of the patient and the recorders.
Study NCT05960552 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: The conventional TEE group
Description: Before cardiopulmonary bypass separation, conventional TEE examinations will be performed within the specified 120 seconds. Then, the expert will also perform a standard comprehensive TEE; the leading cause should also be presented to the attending anesthesiologists and recorders.
Study NCT06557902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone 10.5 mg capsule
Description: Lumateperone 10.5 mg capsule, oral administration
Study NCT06557902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone 21 mg capsule
Description: Lumateperone 21 mg capsule, oral administration
Study NCT06557902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone 5 mg ODT
Description: Lumateperone 5 mg ODT, oral administration
Study NCT06557902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone 10.5 mg ODT
Description: Lumateperone 10.5 mg ODT, oral administration
Study NCT06557902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone 15.5 mg ODT
Description: Lumateperone 5 mg ODT + 10.5 mg ODT, oral administration
Study NCT06557902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone 21 mg ODT
Description: Lumateperone 21 mg ODT, oral administration
Study NCT06281834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifapentine
Description: Children 2-11 years received standard HIV treatment and 3HP (RPT/INH weekly for 12 weeks) for TB prevention. Children \<2 years receive standard HIV treatment, a single-dose of extrapolated weekly RPT/INH, followed by standard INH prophylaxis. Safety and pharmacokinetics will be evaluated.
Study NCT06281834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: All children in this study are living with HIV and thus dolutegravir is a standard part of treatment; in this study we will collect blood samples to measure dolutegravir levels during combination treatment with rifapentine/isoniazid treatment for TB prevention
Study NCT05617196 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual PREHAB
Description: The Virtual PREHAB program begins with a virtual health care team assessment. The physiotherapist will support patients in identifying ways to safely engage in home-based physical activities and in their neighborhoods. Additional weekly 30-minute telephone consultations with the physiotherapist, nurse, and dietitian are provided as well as three 30-minute online consultations are provided; telephone calls will replace these online consults if the patient does not have internet access. Telephone and/or online consults with participants will monitor the progression of the individual through the program, review patient materials, review medication changes, as well as provide recommendations to adopting a physically active lifestyle, diet, well-being, smoking, or other supports available to the patient. Medication changes are monitored by a nurse and any necessary medication recommendations involve the program's medical director, the patient's family physician, and TAVI team.
Study NCT05617196 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: In Nova Scotia, patients are referred to the TAVI program. The TAVI health care team, consisting of a cardiac surgeon, cardiologist, nurse, and geriatric team conduct patient assessments and provide guidance and resources on self management.Once patient assessments are completed, patients are discussed at a multidisciplinary team meeting. When a patient is accepted for TAVI, they are placed on a waiting list which lasts for 3-6 months depending on urgency.
Study NCT06042491 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehabilitation intervention
Description: The intervention consists of exercise, nutritional support and breathing techniques. The exercise component consists of 1) strength training; 2) cardio and 3) stretching. Participants will be encouraged to complete self-directed and/or group sessions >= 3 times per week. Each intervention participant will be provided a unique login to the virtual prehabilitation platform, which is the STRIVE Trial website. The nutrition component includes: 1) protein supplementation; 2) nutrition advice to support healthy eating. For the breathing component, participants will be encouraged to watch the video on Inspiratory Muscle Training (IMT) which involves diaphragmatic breathing and coughing/huffing. They will also be provided with an instruction booklet to take to hospital with them to support postoperative conduct of IMT during early recovery.